Adoptive immune cell therapy has the potential to overcome the problem of delivery and adaptive mechanisms of resistance thought to be, at least in part, responsible for the failure of therapeutically targeting EGFR in GBM [12]. The gene discussed is EGFR; the disease is glioblastoma.